Current evidence suggests there is heterogeneity of resistance mechanisms that include decreased TGFβ-receptor II expression in early and late stage HCC [6] or induction of the inhibitory SMAD7 in advanced HCC [6-8]. The gene discussed is SMAD7; the disease is hepatocellular carcinoma.